One assignee leads clearly with 160 records, well ahead of the fifth-ranked filer at 44 and the tenth at 20. The top 5 assignees together hold 565 of the 1,128 records in scope, or 50.1%, and the top 10 hold 61.1%. Beyond that concentrated group, the ranking runs into a long tail of assignees with only a handful of filings each, so the field is best described as having one dominant filer plus a fragmented rest rather than several evenly matched competitors.

Filing peaked in 2020 at 123 records and fell to 45 by 2024, a 56% decline across that 2021-2024 span — the most recent period that publication lag allows us to treat as complete. Records from 2025 and 2026 are still incomplete because publication typically lags actual filing by around 18 months, so they should not be read as evidence the decline is continuing. The honest read is that activity cooled from its 2020 peak through 2024; anything more recent is still filling in.

This Synlogic Operating Company filing, published 2019-01-10, covers genetically engineered bacteria along with pharmaceutical compositions containing them and methods of using them to attenuate metabolic diseases. It is representative of a claim pattern seen repeatedly among the leading assignees in this dataset: pairing a specific engineered strain with a pharmaceutical composition and a therapeutic method, rather than claiming the engineering technique alone. Anyone designing a metabolic-disease strain therapy should read its granted claims closely before finalizing a delivery or dosing approach that overlaps this composition-and-method structure.